AN2 Therapeutics Inc
NASDAQ:ANTX

Watchlist Manager
AN2 Therapeutics Inc Logo
AN2 Therapeutics Inc
NASDAQ:ANTX
Watchlist
Price: 1.1 USD
Market Cap: 30.1m USD

AN2 Therapeutics Inc
Income from Continuing Operations

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

AN2 Therapeutics Inc
Income from Continuing Operations Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Income from Continuing Operations CAGR 3Y CAGR 5Y CAGR 10Y
AN2 Therapeutics Inc
NASDAQ:ANTX
Income from Continuing Operations
-$51m
CAGR 3-Years
-33%
CAGR 5-Years
-55%
CAGR 10-Years
N/A
Johnson & Johnson
NYSE:JNJ
Income from Continuing Operations
$25.1B
CAGR 3-Years
19%
CAGR 5-Years
9%
CAGR 10-Years
5%
Bristol-Myers Squibb Co
NYSE:BMY
Income from Continuing Operations
$6B
CAGR 3-Years
-3%
CAGR 5-Years
N/A
CAGR 10-Years
13%
Pfizer Inc
NYSE:PFE
Income from Continuing Operations
$9.8B
CAGR 3-Years
-31%
CAGR 5-Years
16%
CAGR 10-Years
2%
Merck & Co Inc
NYSE:MRK
Income from Continuing Operations
$19B
CAGR 3-Years
7%
CAGR 5-Years
31%
CAGR 10-Years
6%
Eli Lilly and Co
NYSE:LLY
Income from Continuing Operations
$18.4B
CAGR 3-Years
45%
CAGR 5-Years
27%
CAGR 10-Years
23%
No Stocks Found

AN2 Therapeutics Inc
Glance View

Market Cap
29.7m USD
Industry
Pharmaceuticals

AN2 Therapeutics Inc is a US-based company operating in Pharmaceuticals industry. The company is headquartered in Menlo Park, California and currently employs 22 full-time employees. The company went IPO on 2022-03-25. AN2 Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing treatments for rare, chronic, and serious infectious diseases with high unmet needs. The firm is focused on advancing its first product candidate, epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial (NTM) lung disease. Epetraborole is a boron-containing, small molecule inhibitor of bacterial leucyl-tRNA synthetase (LeuRS), an enzyme that catalyzes the attachment of leucine to transfer RNA, or tRNA, molecules in protein synthesis. The company is focused on developing epetraborole to treat Mycobacterium avium complex (MAC). The Company’s core technology approach is based on the use of boron chemistry for its research and development initiatives. Boron has a distinctive ability to bind with biological targets through a reversible covalent bond and the potential to address biological targets that have been difficult to inhibit using traditional carbon-based molecules.

ANTX Intrinsic Value
3.23 USD
Undervaluation 66%
Intrinsic Value
Price

See Also

What is AN2 Therapeutics Inc's Income from Continuing Operations?
Income from Continuing Operations
-51m USD

Based on the financial report for Dec 31, 2024, AN2 Therapeutics Inc's Income from Continuing Operations amounts to -51m USD.

What is AN2 Therapeutics Inc's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 5Y
-55%

Over the last year, the Income from Continuing Operations growth was 22%. The average annual Income from Continuing Operations growth rates for AN2 Therapeutics Inc have been -33% over the past three years , -55% over the past five years .

Back to Top